Association of insulin gene VNTR INS -23/Hph1 A>T (rs689) polymorphism with type 1 diabetes mellitus in Egyptian children

Background

Type1 diabetes mellitus (T1DM) has a multi-factorial pathogenesis; the interplay between genetic susceptibility and environmental factors is thought to provide the fundamental element for the disease. Apart from HLA, more than 50 genetic variants are associated with T1DM. INS -23/Hph1 A>T (rs689) is one of the effective loci with inconsistent reports in the literature. Accordingly, this study was designed to define the frequencies of INS -23/Hph1 A>T polymorphism and its association with T1DM in Egyptian diabetic children and their non-diabetic family members as compared to healthy controls.

Methods

Using polymerase chain reaction-restriction fragment length polymorphism methodology, analysis of insulin gene VNTR polymorphism was performed for 496 samples (91 patients, 179 parents, 130 siblings, and 96 controls); parents and siblings were apparently healthy.

Results

INS genotypes and allele frequencies were comparable between patients, non-diabetic siblings, and parents (p = 0.97 and 0.77, respectively). However, the TT/AT genotype and T allele were over-presented in the three family groups compared to controls (p = 0.0015 and 0.0029, respectively).

Comparing patients to controls, the T allele is considered a risk factor for the development of TIDM (OR 2.56, 95% CI 1.42–4.62, p = 0.0017).

INS -23/Hph1 A>T polymorphism showed concordance between patients and their mothers (Kappa = 0.446, p = 0.000) but not with their fathers (Kappa = 0.031, p = 0.765).

Conclusions

INS -23/Hph1 A>T gene polymorphism was shown to be a risk factor for the development of TIDM. This is in agreement with some and in disagreement with other reports. Studies of risk susceptibility factors have to be carried out locally in each community; results cannot be extrapolated from one ethnic group to another.

Type1 diabetes mellitus (TIDM) is one of the most common chronic childhood illnesses [1]. T1DM results from autoimmune destruction of the insulin-producing beta cells in the pancreas [1]. People with a family history of T1DM and type2 diabetes mellitus (T2DM) are six and three times more likely, respectively, to develop these diseases than unrelated individuals [2]. T1DM has a multi-factorial pathogenesis; the interplay between genetic susceptibility and environmental factors is thought to provide the fundamental element for the disease [3]. Alleles or genetic variants associated with T1DM provide either susceptibility to or protection from the disease within a given environmental background [3]. HLA genes have the highest effect on risk susceptibility to TIDM [4]. However, more than 50 loci outside the human leukocyte antigen (HLA) region have been confirmed to affect T1DM [4]. The genetic makeup with the balance between susceptibility and protection alleles determines the age of onset of T1DM [5]. Next in importance to HLA, polymorphisms in the noncoding region of the insulin (INS) gene (IDDM2) contribute to susceptibility to or protection from T1DM [6]. This locus includes a variable nucleotide tandem repeat (VNTR) mini-satellite located at the 5′ end of the insulin gene [6]. There are three main VNTR classes defined by the VNTR size: class I (26–63 repeats), class II (approximately 80 repeats), and class III (140–200 repeats) [7]. Polymorphisms within the insulin gene are in linkage disequilibrium with the VNTR region and can therefore be used as markers for these gene variants [7]. The 223HphI A>T single-nucleotide polymorphism (SNP), a polymorphic sequence in the INS gene, was found to be in strong linkage disequilibrium with the VNTR alleles; the A allele is in linkage with the short (class I), and the T allele is in linkage with the long (class III) VNTR allele [8]

The literature shows inconsistency as regards the association of the A and T alleles with risk susceptibility to TIDM. In some reports, the A allele is claimed to be associated with risk of developing diabetes and the T allele is claimed to be protective [8,9,10,11,12]. Other reports indicate that T allele is the one associated with risk susceptibility [13,14,15] while others deny an impact of either on risk susceptibility to TIDM [16,17,18,19,20].

Risk susceptibility, in general, reflects an interaction between genetic and environmental factors [3]. Ethnic variations in the relative frequency of different alleles as well as exposure to a different local environment lead to variable contribution of a given gene polymorphism to risk susceptibility to one disease or the other [3]. Hence, results cannot be extrapolated from one population to another and such studies have to be locally performed in each community.

Studies performed in Egypt on genetic background of T1DM, including studies of the research team, have so far addressed mainly the contribution of the HLA region and CTLA-4 [21,22,23]. Only one previous study, performed on 25 subjects, addressed the role of INS gene in risk susceptibility to TIDM [24].

In the current study, The INS -23/Hph1 A>T (rs689) was tested in diabetic children, non-diabetic siblings, and parents as compared to normal controls. This may help, together with other genetic information, to predict the possibility of a child, born to a diabetic family, to develop the disease leading to early effective therapy and better management of diabetic children.

On account of the controversy of literature, this study was designed to define the frequencies of INS -23/Hph1 A>T polymorphism and its association with T1DM in Egyptian diabetic children and their non-diabetic family members as compared to healthy controls.

The work was carried out in accordance with the Helsinki Declaration for experiments involving human beings. The study was approved by the Institutional Review Board of the National Cancer Institute, Cairo University (Approval No 200809003.2 on October 28, 2010), and a written informed consent was obtained from all participants or their guardians.

Subjects

The study included 496 subjects: 91index cases with type 1 diabetes mellitus, 179 parents, 130 siblings, and 96 control healthy subjects; parents and siblings were apparently healthy. Nine families were with a single parent; the missing parent either refused to share, was divorced, or unavailable. Eighty-nine (89) families have only one diabetic proband and seven (7.3%) have two or more diabetic probands; only one was included in statistical analysis. All patients are attending an outpatient clinic in the Diabetes Endocrinology and Metabolism Pediatrics Unit, at Cairo University Children’s Hospital. Patient’s ages at the time of the study ranged from 1.5 to < 18 years with a mean of 8.6 ± 4 and a median of 9 years. The age of onset ranged from 1 year to 12.6 years with a mean of 5.3 ± 3.6 and a median of 5 years. Seventeen cases have age of onset ≤ 1 year; patients with age of onset ≤ 6 months were excluded as 95% of patients with diabetes onset < 6 months of age have a monogenic origin [25]. Complete physical examination, anthropometry, and examination for any associated conditions, congenital anomalies, or complications were routinely done for every patient.

The following information was obtained:

1. 1.

   Age of onset for index case (by definition < 18 years).

2. 2.

   Age of onset for other siblings (if any).

3. 3.

   History of diabetes mellitus in the family occurring at any age.

4. 4.

   History of other autoimmune diseases in the family including, among others, autoimmune thyroiditis, pernicious anemia, and Addison’s disease.

DNA analysis and PCR-RFLP testing for INS -23/Hph1 A>T

Genomic DNA was extracted from peripheral blood using the salting out technique [26]. INS-23/Hph I polymorphism was determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method [27]. The PCR reaction mixture contained 50 ng genomic DNA, 0.5 μM of each primer (forward: 5′-AGC AGG TCT GTT CCA AGG-3′ and reverse: 5′-CTT GGG TGT GTA GAA GAA GC-3′), 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 0.2 mM of each dNTP, and 0.75 units Taq DNA polymerase (Promega, USA) in a final volume of 25 μl. The cycle consisted of initial denaturation for 2 min at 95 °C, 32 cycles at 94 °C for 20 s for denaturing, 15 s at 57 °C for annealing, and 30 s at 72 °C for extension with final extension at 72 °C for 10 minutes. The PCR products were digested with the Hph I restriction enzyme at 37 °C for 18 h. After digestion, products were electrophoresed on 2.5% agarose gel and visualized by ethidium bromide staining. The T and A alleles could be distinguished as bands of 231 plus 129 bp and 191 plus 129 bp, respectively (Fig. 1).

INS -23 Hph1 A>T polymorphism. Lane 1: 50 bp ladder, lanes 3 and 7–10: Wild type (AA) 191 and 129 bp; lanes 4-6: heterozygous (AT) 231, 191, and 129 pb

Full size image

Statistical analysis

SPSS version 17.0 was used for data management. Proportions were compared using the chi-square and Fisher exact tests. Odds ratio of genotype(s) was calculated with 95% confidence interval. Parametric and non-parametric tests compared the means of two or more than two independent groups (t test and ANOVA).

Hardy–Weinberg equilibrium (HWE) was evaluated using chi-square test to estimate the study quality. Genotype and allele frequencies were calculated for the described SNPs. The groups were compared using the χ2 test to analyze the statistical significance of the difference in allelic distribution of various polymorphisms in patients and controls. Measurement of agreement Kappa between patients and both parents was calculated using Cohen Kappa coefficient. P value was considered significant at 0.05 level.

Frequencies of rs689 in the different groups are shown in Table 1.

The genotype distribution was comparable between patients, parents, and non-diabetic siblings (p = 0.97). AA was over-represented in the controls while TT and AT were over-represented in the three family groups compared to controls (p = < 0.0015 and 0.0029, respectively).

The distribution of the A and T alleles is comparable between patients, parents, and non-diabetic siblings (p = 0.77). The T allele is over-represented in the three diabetic family groups as compared to the control group (p = 0.0029). Comparing patients to normal controls, the T allele is considered a risk factor for the development of TIDM (OR 2.56, 95% CI 1.42–4.62, p = 0.0017).

By analysis of INS -23/Hph1 A>T polymorphisms in each parent (father and mother) and comparing it with patients, the AA allele was inherited from the mother in 34 cases and from the father in 25 cases, the AT allele was inherited from the mother in 23 cases and from the father in 15 cases while the TT allele was inherited from the mother or the father in one case each (Table 2).

There was concordance between patients and their mothers (concordance rate 58/82, measure of agreement Kappa = 0.446, p = 0.000) but not with their fathers (concordance rate 41/81, measure of agreement Kappa = 0.031, p = 0.765) (Table 2).

There was no association between INS -23/Hph1 A>T polymorphisms in patients and other autoimmune diseases, e.g., Hashimoto’s thyroiditis, rheumatoid arthritis, and rheumatic heart disease or Crohn’s disease (P = 0.23).

Apart from MHC (IDDMI), more than 50 Non-HLA genes were reported to contribute to risk susceptibility to TIDM [4]. Among these, INS gene (IDDM2) is claimed to be the most effective; INS gene, also, plays an important role in the progress of other endocrine diseases [28].

Polymorphisms within the insulin gene are in linkage disequilibrium with the VNTR region and were used as a surrogate marker for the gene variants in several studies [10, 11, 29, 30].

In the current study, we analyzed the 223HphI A>T in 91 diabetic children and their family members as well as 96 normal controls. We included parents and siblings as they are sharing, at least partly, the genotype(s) with the patients; the parents are not diabetic and the siblings are not diabetic so far. Our results indicate that T allele carriers are at 2.56 folds risk to develop TIDM.

In agreement with our results, Peterson et al. [15] reported a 2.44 folds increased risk associated with the INSrs689 T allele. Other studies had the same conclusion with a 4.5 folds risk associated with homozygous TT genotype [13] and 4.02, 4.4, and 6.96 folds risk in three Israeli Jewish populations [14].

Other reports, however, deny any impact of INSrs689 polymorphism on risk susceptibility to TIDM [16,17,18,19,20]. The study of Benedek et al. [14] that documented the association of T allele with ITD in three Jewish populations failed to prove that association in the Israeli Arabs which highlights the effect of ethnicity. They attributed their finding to the higher frequency of the VNTR class I variant allele 814, among Arabs, that does not predispose to T1D when paternally inherited [31].

In contrast to our results, a meta-analysis performed by Zhang et al. [32] documented the A allele of the-23HphI polymorphism as the risk allele and the T as the protective allele.

The only previous Egyptian study is also in contrast with our results showing the A allele of the-23HphI polymorphism as the risk allele and the T as the protective allele. However, the sample size was too small with 25 cases and 20 controls; in their series, all patients had class I and all controls had class III. Also all family members had class III except for three mothers with class I with no comment on the distribution of wild, hetero, and homozygous in the different groups [24].

A mechanistic explanation of the association has been proposed, as the A T1DM-risk allele, suggested in some studies, is claimed to relate to lower levels of insulin transcription in thymus leading to non-effective deletion of insulin-specific auto-reactive T cells [9, 29, 33,34,35]. This explanation may be questioned from several aspects. First, the genotype claimed to be associated with lower levels of insulin transcription in the thymus is the one associated with higher level of production in the pancreas. This leads to the second point of consideration; breaking of central tolerance is not the only mechanism in autoimmune diseases but peripheral tolerance also plays a major role [36]. Breaking of peripheral tolerance is affected by many environmental factors including viral infections and others with marked variability in different communities.

Another potential explanation of the discrepancy is that most studies, including ours, did not determine the subclasses of VNTR I and VNTR III. For instance the assumed protective role of VNTR III is claimed to be attributed to VNTR IIIA/IIIA [10]. Also, VNTR class I variant allele 814 does not predispose to T1D when paternally inherited [31].

Our study showed maternal rather than paternal concordance with TIDM children (Kappa = 0.446, p = 0.000 and Kappa = 0.031, p = 0.765, respectively). This could be also contributing to the discrepancy in the literature as the parental source of inheritance affects the impact of different genes on risk susceptibility [7, 30, 31].

Apart from this mechanistic theory, risk susceptibility associated with gene polymorphisms is largely affected by ethnic variations including the relative genotype frequency in different populations which varies from one community to another [12, 13, 16, 33, 34, 37].

We report that the INS -23/Hph1 A>T polymorphism is a significant risk susceptibility locus to TIDM in Egyptian children; carriers of the T allele are at 2.56 folds risk to develop the disease. These results are in agreement with some and in disagreement with other previous studies. The discrepancy of results may also indicate that more than one mechanism is involved with central tolerance vs. peripheral tolerance playing the major role. In general, this highlights the importance of performing susceptibility studies locally; findings from one ethnic group or population cannot be extrapolated to others. Limitations of this study include the relatively small number of patients and control groups. Also, further studies integrating different TIDM susceptibility genes are highly recommended.

All data are included in the manuscript

TIDM:

Type1 diabetes mellitus

T2DM:

Type2 diabetes mellitus

INS:

Insulin

IDDM:

Insulin-dependent diabetes mellitus

PCR-RFLP:

Polymerase chain reaction-restriction fragment length polymorphism

VNTR:

Variable nucleotide tandem repeat

SNP:

Single-nucleotide polymorphism

None

Funding

This work was supported by the US/Egypt conjoint fund IDCODE: BIO9-002-010, Contract/Agreement No. 268.

Affiliations

1. Clinical Pathology Department, NCI, Cairo University, Fom El-Khalig Square, Cairo, 11796, Egypt

   • Azza M. Kamel
   •  & Gamal T. A. Ebid

2. Pediatric Department, Faculty of Medicine, Cairo University, 1Abo-Elrih square, El-Sayeda Zeinab, Cairo, 11617, Egypt

   • Marwa F. Mira
   • , Mona Mamdouh
   • , Maha Amin
   • , Nora Badawy
   • , Hafez Bazaraa
   • , Amani Ibrahim
   •  & Nermine Salah

3. Faculty of Applied Medical Sciences, October 6 university, Giza, 12585, Egypt

   • Samar H. Kassem

4. Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Kasr El-Aini Hospital, Manial, Cairo, 11451, Egypt

   • Eman R. Radwan

5. October 6 University, Central Axis, 1/1 piece 6 October, Giza, 12585, Egypt

   • Samar H. Kassem

Contributions

AMK made the work design, supervised the data analysis, and finalized the manuscript. GT participated in the molecular genetic testing. SH participated in the molecular genetic testing and drafted the manuscript. ERR participated in the molecular genetic testing and revised the manuscript. MFM participated in the study design, collected the patient’s samples, and integrated the clinical and laboratory data. MMH, MA, NEB, HMB, and AI participated in the study design, followed the patients clinically, and supplied the clinical data. NS supervised the clinical part and finalized the clinical data. All authors approved the manuscript

Corresponding author

Correspondence to Samar H. Kassem.

Ethics approval and consent to participate

The work was carried out in accordance with the Helsinki Declaration for experiments involving human beings. The study was approved by the Institutional Review Board of the National Cancer Institute, Cairo University (Approval No 200809003.2 on October 28^th 2010), and a written informed consent was obtained from all participants or their guardians.

Consent for publication

NA

Competing interests

The authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reprints and Permissions